Walter Taal

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick, Thierry Gorlia, Martin Bendszus et al. · New England Journal of Medicine · 2017 · 949 citations · Full text

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 738 citations

Neuro-oncology, Oncology, Single-agent Bevacizumab +10

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

Walter Taal, Dieta Brandsma, Hein G. de Bruin et al. · Cancer · 2008 · 458 citations · Full text

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 392 citations · Full text

Catnon Trial, Treatment Strategies, Radiation Therapy +13

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 307 citations · Full text

Surgical Oncology, Health Sciences, Glioma +11